Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 4 Biliary Tract Neoplasms 3 Pancreatic Neoplasms 2 Carcinoma, Neuroendocrine 2 Carcinoma, Hepatocellular 2 Advanced Colorectal Cancer 2 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1 Refractory Metastatic Digestive System Carcinoma 1 Neuroendocrine Tumor Grade 3 1 Head and Neck Cancers - Salivary Gland 1 Gallbladder Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Advanced Non-Small Cell Lung Cancer 1

Interventions

Doxorubicin 19 Radiotherapy 10 Ifosfamide 10 apatinib 9 anlotinib 8 Cyclophosphamide 8 camrelizumab 7 Vincristine 5 Dactinomycin 5 toripalimab 3 Trabectedin 3 Radiation Dose Hypofractionation 3 Ipilimumab 3 Gemcitabine 3 Etoposide 3 Docetaxel 3 selinexor 2 ribociclib 2 envafolimab 2 brostallicin 2 Topotecan 2 Thalidomide 2 Temozolomide 2 Sorafenib 2 Oncolytic Virotherapy 2 Nivolumab 2 Neoadjuvant Therapy 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Sarcoma × surufatinib × Clear all

NCT05106777 2023-04-12

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡